Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02291's PS Ratio is ranked worse than 76.46% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 2.92
vs HKSE:02291: 6.29
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lepu Scientech Medical Technology (Shanghai) Co PS Ratio Related Terms
Lepu Scientech Medical Technology (Shanghai) Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co PS Ratio Chart
Lepu Scientech Medical Technology (Shanghai) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Scientech Medical Technology (Shanghai) Co PS Ratio vs Medical Devices & Instruments Industry
Lepu Scientech Medical Technology (Shanghai) Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lepu Scientech Medical Technology (Shanghai) Co's Share Price of today is HK$10.49.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lepu Scientech Medical Technology (Shanghai) Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a PS Ratio of 6.29 as of Sep. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. This is 63% below median its historical median of 17.15. Over the past decade, Lepu Scientech Medical Technology (Shanghai) Co's PS Ratio has ranged from 5.19 to 37.15. According to the industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #614 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 76.5%.
Is Lepu Scientech Medical Technology (Shanghai) Co's PS Ratio too high?
Lepu Scientech Medical Technology (Shanghai) Co's current PS Ratio of 6.29 is 63% below median its 10-year median of 17.15. Over the past 10 years, this metric has ranged from a low of 5.19 to a high of 37.15. The Medical Devices & Instruments industry median PS Ratio is 2.92. Lepu Scientech Medical Technology (Shanghai) Co's value of 6.29 is 115.4% above this industry median. Based on the distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #614 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #614 out of 803 companies for PS Ratio. This places Lepu Scientech Medical Technology (Shanghai) Co in the lower half of its industry. The industry median PS Ratio is 2.92. Lepu Scientech Medical Technology (Shanghai) Co's value of 6.29 is 115.4% above this benchmark. Historically, Lepu Scientech Medical Technology (Shanghai) Co's own PS Ratio has ranged from 5.19 to 37.15 over the past decade. While the company's 10-year median is 17.15 vs. the industry median of 2.92, Lepu Scientech Medical Technology (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.92, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Scientech Medical Technology (Shanghai) Co's current PS Ratio of 6.29 is 115.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Scientech Medical Technology (Shanghai) Co's current PS Ratio is 6.29, which is 63% below median its own 10-year median of 17.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$45.87, compared to a current price of HK$10.49 — trading 77.1% below its estimated fair value. The current PS Ratio is 6.29, which is 63% below median its 10-year median of 17.15 and 115.4% above the Medical Devices & Instruments industry median of 2.92. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current PS Ratio is 6.29 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$10.49 is trading 77.1% below its estimated GF Value™ of HK$45.87.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
PS Ratio: 6.29 (63% below median its 10-year median of 17.15)
GF Value™: HK$45.87 vs. price of HK$10.49 (77.1% below fair value)
Industry Position: 115.4% above the Medical Devices & Instruments median (#614 of 803)
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
82GF Score
Get the complete analysis for HKSE:02291
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
